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Multi-cellular systems require complex signaling mechanisms for proper tissue function, to mediate
signaling between cells in close proximity and at distances. This holds true for the islets of Langer-
hans, which are multicellular micro-organs located in the pancreas responsible for glycemic control,
through secretion of insulin and other hormones. Coupling of electrical and metabolic signaling
between islet b-cells is required for proper insulin secretion and effective glycemic control. b-cell
speciﬁc coupling is established through gap junctions composed of connexin36, which results in
coordinated insulin release across the islet. Islet connexins have been implicated in both Type-1
and Type-2 diabetes; however a clear link remains to be determined. The goal of this review is to
discuss recent discoveries regarding the role of connexins in regulating insulin secretion, the regu-
lation of connexins within the islet, and recent studies which support a role for connexins in diabe-
tes. Further studies which investigate the regulation of connexins in the islet and their role in
diabetes may lead to novel diabetes therapies which regulate islet function and b-cell survival
through modulation of gap junction coupling.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction also beginning to emerge. Recent studies in mouse models haveThe pancreatic islets of Langerhans are responsible for blood
glucose homeostasis through the regulated secretion of insulin
and other hormones. In b-cells within the islet, membrane depolar-
ization and calcium inﬂux drives the coordinated release of insulin.
Gap junctions are intercellular channels, composed of two connex-
on hemi-channels each made up of six connexin subunits, which
readily transfer ions, metabolites and other small molecules
between cells. For a more in depth review on connexins in general
and their role in the endocrine system, we refer readers to the
review article by Bosco et al. [1]. In the islet, gap junctions com-
posed of connexin36 (Cx36, also known as Gjd2) provide electrical
and metabolic coupling between b-cells which regulates electrical
activity and insulin secretion. Under high glucose, gap junctions
facilitate the coordination of electrical activity across the islet
which leads to synchronized release of insulin from individual
b-cells. Under low glucose, gap junctions repress electrical activity
which contributes to the inhibition in the release of insulin. While
the role of Cx36 gap junctions is becoming increasingly established
in the islet, a link between gap junction coupling and diabetes isshown a correlation between decreased gap junction coupling, dis-
ruptions to glucose homeostasis and altered islet function; similar
to that observed in models of diabetes. This suggests that gap junc-
tion coupling may be one underlying factor, of many, which con-
tributes to disease development. As such, this review will discuss
the speciﬁc role of Cx36 gap junctions in islet function and insulin
secretion, the known pathways for regulation of Cx36, and current
evidence for the role of Cx36 in Type 1 and Type 2 diabetes. We
also note that discussion of a number of roles Cx36 plays in the is-
let can also be found in reviews by Meda and colleagues [2–5] or by
Perez-Armendariz [6]. Current evidence suggests that regulation of
insulin secretion from the islet can be modulated through gap
junction coupling. Understanding the regulation of Cx36 gap junc-
tions and the role they play in diabetes has the potential to uncover
new therapies which restore more physiological blood glucose
control and which could potentially deter the onset of disease.2. The role of connexins in the islet
2.1. Connexins and gap junctions
In the human genome, 22 connexin species have been
identiﬁed, while only 19 have been identiﬁed in the mouse [7,8].
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tein, where for example Cx36 has a molecular weight of 36 kDa [9].
Most connexins share a very similar gene structure and therefore a
similar protein structure, where all connexins are composed of 4
membrane spanning domains connected by 2 extracellular and 1
intracellular loop [8]. The N-terminal, 2 extracellular loops and 4
transmembrane regions are highly conserved between different
connexins, while the intracellular loop and C-terminal are highly
variable [10]. Both the N- and C-terminal are located in the cyto-
plasm, positioning them for post-translational modiﬁcations by
intracellular kinases and phosphatases [11], and for interactions
with connexin-associated proteins [12].
Connexin proteins oligomerize around a central hydrophilic
space into a 6-protein hemi-channel called a connexon during
trafﬁcking from the ER to the Golgi complex [13]. Connexons may
be homomeric, composed of only one type of connexin protein, or
heteromeric, composed of different species of connexins [14].
Connexons are then trafﬁcked to the plasma membrane via
Golgi-derived vesicles mediated through microtubules or the actin
cytoskeleton [15]. Connexons are inserted into a lipid raft in the
membrane [13], where they can rapidly diffuse and aggregate at
tight junctions or other non-junctional areas of the membrane. At
tight junctions, adhesion molecules such as zonula occludens-1
on the surface of neighboring cells have decreased the gap between
cells to 2 nm [16,17]. At this point, connexon hemi-channels may
remain uncoupled [18], or they may interact with a connexon from
a neighboring cell via extracellular loops and form an intercellular
channel. In many cell types uncoupled hemi-channels can play a
role in cell signaling. However, no known role for uncoupled Cx36
hemi-channels has been established in the islet to date and recent
studies suggest that b-cells do not have functional uncoupled
hemi-channels [19].
Connexons which have formed intercellular channels aggregate
in the membrane and form plaques, termed gap junctions [20]. Gap
junctions provide electrical and metabolic coupling between cells
[21]. Electrochemical gradients drive the rapid diffusion of ions,
metabolites, nucleotides, small peptides and other small molecules
[16,22], where the selectivity and conductance of gap junctions to
these molecules is largely determined by the species of connexin
that comprises the hemi-channels [23]. Although gap junctions
are made up of many intercellular channels, the individual connex-
in channels are only open about 10% of the time [24]. Gating of
connexin channels can be controlled through environmental fac-
tors, such as electric current and voltage across the channel, cyto-
solic pH, or changes in intracellular free-calcium activity ([Ca2+]i)
[25,26]; as well as through post-translational phosphorylation
[11]. Connexin channels are also very short lived, with a half-life
of 4 h. Gap junctions are internalized from the center of a plaque
where the hemi-channel and connexin protein are degraded, while
new hemi-channels are inserted at the periphery of the plaque
[13,14]. While gap junctions play a role in cell signaling through
electrical and metabolic coupling, recent evidence suggests that
connexin hemi-channels may also effect changes in gene expres-
sion and cell proliferation through interactions with other proteins
or through insertion into non-junctional regions of the plasma
membrane [27].
2.2. Connexin36 gap junctions
Insulin-secreting b-cells within the pancreatic islet are exclu-
sively coupled by Cx36 gap junctions in mice, and strongly coupled
by Cx36 gap junctions in humans [28–30]. To date, Cx36 has been
found to be highly expressed in the brain [31], the adrenal medulla
[32], the retina [33], in the murine carotid body, ileum, and colon
[34], as well as the pancreatic islet [30]. While Cx36 is expressed
by insulin producing b-cells in the islet, it has also been reportedto be expressed in non b-cells [30]. Data in studies examining elec-
trical activity within the islet suggest that coupling may occur be-
tween a-cells and b-cells based on synchronous oscillations being
observed [35]. However, direct evidence of functional gap junc-
tions has only been found between b-cells [36]. Also recent studies
from our lab have demonstrated that no functional gap junctions
exist between a- and b-cells [submitted]. Cx36 gap junction cou-
pling has been found to be very heterogeneous in mouse islets
[28,36]. Cx36 gap junctions studied in b-cells are distinct from
gap junctions composed of other connexin species in that they
preferentially exchange cationic molecules [37], are minimally
voltage sensitive with a half-activation voltage of only ±85 mV
[38], and have a small unitary conductance (6 pS) [36]. Compared
to gap junctions formed by other species of connexins, Cx36 gap
junction only have an open probability of 0.8% [39].3. Connexin36 regulation of insulin secretion
3.1. Role of connexin36 under high glucose
In b-cells, a series of metabolic and electrical events regulates
insulin secretion in response to elevations in blood glucose. Glu-
cose uptake and metabolism leads to a generation of ATP, closure
of ATP-sensitive potassium channels (KATP), subsequent membrane
depolarization, activation of voltage gated calcium channels and an
elevation of [Ca2+]i, as outlined in Fig. 1. This [Ca2+]i elevation trig-
gers insulin granule exocytosis and release from individual b-cells.
The dynamics of insulin release are tightly coupled with electrical
activity and therefore calcium signaling across the islet. Glucose
driven oscillations in electrical activity modulated by KATP channel
gating leads to oscillations in [Ca2+]i [40]. Glucose stimulated
insulin secretion is biphasic, with a burst release in the 1st phase
and a pulsatile release in the 2nd phase [41]. While the mechanism
underlying biphasic release of insulin are under debate, one
proposed mechanism is that different phases originate from two
separate pools of insulin granules; one population which is docked
to the plasma membrane and is readily available for insulin re-
lease, and one population of reserve granules which must be traf-
ﬁcked to the cell membrane for insulin release. The initial pulse of
glucose stimulated [Ca2+]i stimulates release of insulin from
docked granules, resulting in the initial increase of insulin charac-
terized as 1st phase release. The subsequent oscillations in [Ca2+]i
trigger exocytosis of insulin granules in a pulsatile manner, charac-
terized as the 2nd phase insulin release [41]. Another theory is that
the biphasic nature arises from two subpopulations of b-cells
which exclusively respond to during either the ﬁrst or second of
insulin secretion [42]. However, the action of Cx36 gap junctions
in coordinating b-cell [Ca2+]i and insulin responses across the islet
argues against this.
Under stimulatory levels of glucose, electrical coupling provided
by Cx36 gap junctions allows for transfer of a depolarizing current,
synchronization of KATP channel-regulated membrane depolariza-
tion, and the coordination [Ca2+]i oscillations across the islet
[28,29,43], as depicted in Fig. 1. As such insulin secretion is released
in a coordinated and oscillatory fashion. This has been demon-
strated in isolated islets frommice with knockout of the Cx36 gene,
Gjd2. In one study, islets from Cx36 deﬁcient mice showed a loss of
glucose-stimulated [Ca2+]i oscillations and a loss of pulsatile insulin
secretion [29]. Further studies in Cx36 deﬁcient isolated islets have
shown the loss of [Ca2+]i oscillations arises from a loss of synchro-
nization between b-cells, where individual b-cells still show irreg-
ular, heterogeneous oscillations that lack any synchronization
[28]. This is similar to the irregular and heterogeneous oscillations
observed in isolated b-cells, dissociated from the islet [44] and is
consistent with Cx36 being the sole connexin that forms gap
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Fig. 1. Role of Cx36 in regulating electrical activity and insulin secretion under high glucose conditions. (A) Under high glucose, gap junctions synchronize membrane
depolarization (Vm), [Ca2+]i, and insulin secretion, by promoting a depolarizing current (ICa), including diffusion of Ca2+. (B) Coordinated [Ca2+]i oscillations in cells of a wild-
type islet with normal gap junction coupling (Cx36+/+, upper panel) generating overall pulsatile [Ca2+]i across the islet. In cells of an islet lacking gap junction coupling (Cx36/,
lower panel) there is a lack of any synchronization between heterogeneous and irregular [Ca2+]i oscillations, leading to a lack of overall pulsatile [Ca2+]i across the islet. Data in
B reproduced from [22].
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islets from Cx36 deﬁcient mice show an initial ﬁrst phase release
with reduced amplitude occurring over a longer duration, which
is consistent with the initial [Ca2+]i elevation lacking coordination
among b-cells. Cx36 gap junctions also likely coordinate [Ca2+]i
oscillations in human islets [45]. KATP channel-independent mech-
anisms of insulin release have been identiﬁed, often collectively
termed as ‘amplifying’ pathways [46]. One such amplifying path-
way involves cyclic adenosine monophosphate (cAMP) which regu-
lates insulin granule trafﬁcking to the plasma membrane.
Oscillations in cAMP have been observed which contributes to pul-
satile insulin release [47], and these are coordinated across b-cells
within the islet [48], however it is unknown whether gap junctions
or an alternative mechanism synchronizes these oscillations in
cAMP, as well as the dynamics of other amplifying pathways.
Insulin is also released in vivo in a biphasic fashion, which is
linked to the dynamics of insulin release from isolated islets. For
example the pattern of insulin oscillations in a mouse correlates
strongly with the pattern of calcium oscillations in islets isolated
from that mouse [49]. In humans, it is well established that the
ﬁrst phase of insulin secretion is important for insulin action. The
pulsatile nature of the second phase of insulin secretion in vivo
has also been linked to enhanced insulin action [50], particularly
in terms of enhancing hepatic insulin signaling [51]. In vivo studies
in Cx36 deﬁcient mice reveal that Cx36 is important for glucose
homeostasis, as deletion of Cx36 leads to signiﬁcant glucose intol-
erance [52]. Mice retain normal fasting glucose levels and are
therefore not overtly diabetic, but have a ‘prediabetic’ phenotype.
Importantly a deletion of Cx36 signiﬁcantly impacts the dynamics
of in vivo insulin secretion [52]. Speciﬁcally, a decrease in 1st phase
insulin secretion and decrease in pulse size (but not frequency) in
the 2nd phase of insulin secretion is observed, consistent with
measurements in isolated islets. However mice retained normal
plasma insulin levels and insulin sensitivity. The glucoseintolerance that follows a loss of Cx36 therefore likely results from
the disrupted insulin dynamics, which is consistent with the
importance of 1st phase insulin for insulin action as discussed
above, as well as pulsatile insulin. Interestingly, such disruptions
to insulin secretion dynamics are also observed in Type 2 diabetes
and pre-diabetes [53–55], suggesting a potential role for Cx36 in
islet dysfunction underlying diabetes [56]. Further discussion on
this topic can be found in the section on Type 2 diabetes below.
3.2. Role of connexin36 under basal glucose
At low (basal level) glucose, Cx36 gap junctions coordinate
KATP-driven hyperpolarization across b-cells within the islet [57],
as depicted in Fig. 2. It has long been known that isolated b-cells
are highly heterogeneous in the regulation of insulin release at
high and low glucose levels. As mentioned above, the electrical
activity of individual b-cells or b-cells in islets lacking Cx36 has
been found to be heterogeneous, with spontaneous bursts of
[Ca2+]i occurring at basal glucose [44,58]. While the source of this
heterogeneity is unknown, Cx36 gap junctions have been found
to suppress this spontaneous [Ca2+]i at basal glucose [29,59]. It
has been proposed that Cx36 channels mediate the transfer of
hyperpolarizing currents between b-cells, and therefore allow less
active cells to prevent membrane depolarization and suppress
more active cells [57–59]. For example, studies in isolated islets
discovered that inhibiting KATP channels in the majority of b-cells
in an islet did not result in elevated [Ca2+]i at low glucose. Those
neighboring cells with normal KATP channel regulation, which are
coupled through Cx36 gap junctions, served to suppress the electri-
cal activity in excitable cells that had inhibited KATP channels [57].
Given the extensive heterogeneity present in islets, this mecha-
nism involving Cx36 closely regulates insulin secretion under basal
glucose levels by overcoming b-cell heterogeneity to limit the
range of glucose levels that stimulate insulin secretion.
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Fig. 2. Role of Cx36 in regulating electrical activity and insulin secretion under low glucose conditions. (A) Gap junctions mediate a suppression of electrically active cells
with reduced KATP activity through a hyperpolarizing current (IK), and thus suppress [Ca2+]i and insulin secretion. (B) Fraction of cells exhibiting dynamic changes in [Ca2+]i as
a function of glucose concentration in wild-type islets with normal gap junction coupling (Cx36+/+) and islets lacking gap junction coupling (Cx36/), showing a right-shift
and sharpening of the dose-response in the presence of Cx36. (C) [Ca2+]i in cells of an islet at 5 mM glucose showing largely silent behavior in wild-type islets with normal gap
junction coupling (Cx36+/+, upper panel), but signiﬁcant presence of spontaneous [Ca2+]i elevations in cells of an islet lacking gap junction coupling (Cx36/, lower panel).
Data in B and C reproduced from [51].
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insulin release in Cx36 deﬁcient isolated islets [29,60], other stud-
ies have reported that no increase in basal insulin release is ob-
served in Cx36 deﬁcient islets, despite [Ca2+]i levels being
elevated [58]. In-vivo, fasting insulin and glucose is also unchanged
in Cx36 deﬁcient mice [52]. This contrasts with elevated [Ca2+]i and
insulin release observed in isolated b-cells. This apparent contra-
diction is thought to be due to other mechanisms of inter-cellular
signaling, possibly including EphA-ephrin-A regulation of insulin
granule trafﬁcking and exocytosis, which acts to suppress insulin
release at basal glucose levels even in the absence of gap junction
coupling [58,61].
Over-activity of KATP channels in b-cells underlies the majority
of cases of neonatal diabetes [62]. Similar to the ability of Cx36
gap junctions to suppress electrical activity at basal glucose,
Cx36 gap junctions exacerbate the clamping of b-cell electrical
activity and insulin release at elevated glucose levels under condi-
tions of KATP–overactivity [63,64]. Reducing Cx36 gap junction cou-
pling in mice expressing overactive KATP channels led to a partial
recovery in glucose-stimulated [Ca2+]i and insulin release and im-
proved glucose control. This shows the importance in the proper
balance of Cx36 gap junctions and KATP channels in regulating islet
electrical activity. While the role of Cx36 in regulating electrical
activity and insulin secretion at low and high glucose levels is
increasingly well established; connections between the loss of cou-
pling and development of disease remains to be fully determined.
3.3. Role of other connexins in the islet
Although Cx36 is well established to be expressed in islet
b-cells to regulate insulin secretion, other connexins are also found
within the islet. Previous studies have found that cells within the
islet contain mRNA for Cx43 and Cx45 in mice and Cx30.3, Cx31,
Cx31.1, Cx31.9, Cx37, Cx43 and Cx45 in human pancreas [7]. Somespecies, such as Cx43 and Cx32 are expressed in vasculature or
exocrine tissue respectively, and are not directly expressed in b-
cells. However heterotypic channels (composed of connexons of
two different connexin species) could potentially form between
exocrine tissue or vasculature and b-cells [65,66]. For example, a
recent study has found a correlation between Cx36 expression
and changes in glucose stimulated islet blood cell ﬂow rates [67].
This suggests a connection between b-cell electrical coupling and
vascular regulation of blood ﬂow; however the mechanism behind
this regulation is still unclear.
Recently, however, another connexin isoform has been found
to be expressed in b-cells. Connexin 30.2 (Cx30.2) was found to
be highly expressed in mouse b-cells and vascular endothelial
cells and was spatially associated with Cx36. This suggests that
these connexin species may form heteromeric connexon hemi-
channels and gap junctions [68]. These ﬁndings could explain
the heterogeneity of Cx36 gap junction coupling across the islet,
as mouse Cx30.2 gap junctions have a lower unitary conductance
than Cx36 channels in connexin expressing cell lines [69]. Gap
junctions may also be formed between b-cells and vascular endo-
thelial cells through heterotypic Cx30.2 and Cx36 connexon inter-
actions. This may suggest a role for Cx30.2 in glycemic control as
previous studies in rat retina have shown high glucose down-reg-
ulates Cx30.2 protein production. However further study is re-
quired to better understand the role of Cx30.2 in islet function
and insulin secretion [70], as well as the role of other connexins
in the islet.
4. Regulation of connexins in the islet
4.1. Gene expression and transcription
While most connexins share a common gene structure, the spa-
tial and temporal expression of connexin genes varies greatly by
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that codes for Cx36, has been observed with maturation of mouse
islets. Young and adult b-cells were found to express higher levels
of Gjd2 than fetal and newborn b-cells, while no changes in other
connexin species, such as Cx43, were observed [71,72]. This role
of Cx36 gene expression in early development has not been studied
in depth, however recent studies have linked the activation of Cx36
gene expression with the increased production of transcription fac-
tors which determine b-cell differentiation [72]. This suggests that
Cx36 may be a marker of b-cell differentiation. In mature b-cells,
basal expression of Gjd2 is transcriptionally regulated by the neu-
ron-restrictive silencer element (NRSE) located in the promoter re-
gion of the Cx36 gene, where RE-1 silencing transcription factor
(REST) can bind this region and inhibit expression of Gjd2 [73].
The molecular regulation of Gjd2 expression and transcription
has also not beenwell studied in b-cells. One study has shown tran-
scriptional control of Gjd2 with estrogen and progesterone in neu-
ronal cells; however evidence for similar regulation in b-cells has
not been established [74]. Another study has found increased
expression of Cx36 mRNA with glucocorticoids in b-cells of insulin
resistant mice, however the mechanisms of this regulation are not
clear [75]. While few signaling pathways underlying connexin gene
expression have been identiﬁed across various cell types, gene
transcription has been shown to be regulated by a variety of molec-
ular treatments. For example, Cx43 transcription is elevated by
treatment with cAMP elevating agents [76], glucocorticoids [77],
estrogen [78], parathyroid hormone, and prostaglandin [79].
Transcriptional regulation of Cx43 may also be transactivated by
the Wnt-1 signaling pathways, however further study is required
to determine which signaling elements are involved [80]. Although
little is known about Gjd2 gene or transcriptional regulation, future
studies utilizing known regulators of other connexins may eluci-
date these mechanisms in b-cells. Regulation of Cx36 gene expres-
sion is outlined in Fig. 3.
4.2. Gap junction gating through connexin phosphorylation
The majority of connexins have been found to be regulated by
phosphorylation [11]. Phosphorylation occurs on the cytoplasmic
C-terminal of the connexin protein, on either serine/threonine or
tyrosine residues [16]. While no direct evidence has been found
to support phosphorylation of Cx36 in the islet, studies have
shown that Cx36 contains serine/threonine and tyrosine residues
in different locations on the C-terminal, whose sites in other con-
nexins are readily phosphorylated. This highly suggests phosphor-
ylation of C-terminal residues as mechanism of Cx36 gap junction
regulation [16]. Phosphorylation of connexin proteins is thought to
control connexon trafﬁcking, assembly into gap junctions, and
most notably channel gating. Different protein kinases are thought
to phosphorylate different residues on the C-terminal, differen-
tially affecting channel conductance via these mechanisms [81].
In mouse retina, Cx36 can either be phosphorylated by protein ki-
nase A (PKA) which decreases Cx36 gap junction coupling or PKA
can activate protein phosphatase 2A which dephosphorylates
Cx36 and increases gap junction coupling [82,83]. In neuronal cells
Cx36 can be phosphorylated by calcium/calmodulin-dependent
protein kinase (CaMKII) which increases Cx36 gap junction cou-
pling [84]. Currently no other kinase which phosphorylate Cx36
have been identiﬁed; however protein kinase C (PKC) and mitogen
activated protein kinase (MAPK) have been shown to phosphory-
late several other connexin species and have been implicated in
the regulation of Cx36 gap junctions (Fig. 3) [85]. Future studies
in the islet are required to determine if these mechanisms of phos-
phorylation and channel gating occur via similar mechanisms in is-
let b-cells.4.3. Trafﬁcking
While the cycle of connexon trafﬁcking has been fairly well
established, it has not been studied signiﬁcantly in b-cells. The life
cycle of a connexon involves trafﬁcking from the trans-Golgi net-
work (TGN) to the plasma membrane, insertion into the membrane
and assembly into gap junctions, internalization, and trafﬁcking to
the lysosome or proteasome for degradation [86]. Trafﬁcking of
connexons to the plasma membrane occurs via one of two mecha-
nisms: (1) microtubule-dependent vesicle trafﬁcking or (2) traf-
ﬁcking directly from the TGN (Fig. 3) [15]. While connexon
trafﬁcking via microtubules is well established, more recent stud-
ies also suggest a role for microtubules in directing the location of
gap junction formation [15]. The secondary pathway for connexon
trafﬁcking involves the direct transport of connexon containing
vesicles to the plasma membrane. Recent evidence suggests that
consortin, a TGN cargo receptor present in transport vesicles and
on the plasma membrane, is responsible for targeting connexons
to the plasma membrane and facilitating this trafﬁcking mecha-
nism [87]. As these mechanisms appear to be conserved across sev-
eral species of connexins, the regulation of Cx36 trafﬁcking and
recycling may follow a similar pathway in b-cells.
The regulation of these connexon trafﬁcking pathways is not
well understood, even for connexin species and cell types which
have a deﬁned trafﬁcking mechanism. However a few regulatory
pathways have been identiﬁed. In cardiac cells, studies have shown
that increases in intracellular cAMP and the resulting activation
Epac2 lead to increased Cx43 trafﬁcking [88]. Epac2 is active in
b-cells and important for insulin secretion [89], and therefore
may represent a potential mechanism for the regulation of gap
junction trafﬁcking, assembly and coupling. In cardiomyocytes,
EphB signaling down-regulates gap junction coupling [90]. It has
been suggested that EphB regulation of gap junction coupling is
due to changes in trafﬁcking of connexons to and from the mem-
brane [91]. However, additional studies are required to distinguish
between effects on connexon trafﬁcking and gap junction assembly
as well as to verify this mechanism in b-cells. Factors which effect
TGN vesicle formation, microtubule formation, and vesicle trafﬁck-
ing, may therefore be attractive targets for the regulation of con-
nexins and gap junction coupling.
4.4. Environmental factors
Environmental factors have been shown to play a role in the
regulation of Gjd2 expression and transcription in b-cells. Increases
in Cx36 gap junction coupling have been shown under short peri-
ods (1 h) of high glucose [92]. In contrast, prolonged periods
(24 h) of high glucose have been shown to decrease Gjd2 expres-
sion. This suggests that under chronic hyperglycemia, such as is
seen in Type 2 diabetes, decreases in Cx36 gene expression may
be observed [93]. Similarly, conditions of lipotoxicity, caused by
chronic exposure to free fatty acids, also decreased Cx36 gene
expression [45]. Recent studies have shown that free fatty acids
and hyperglycemia upregulate the transcriptional regulator induc-
ible early repressor 1 (ICER-1), and decrease Gjd2 gene expression
in mouse islets [93–95]. As both hyperglycemia and hyperlipid-
emia are present in Type 2 diabetes, this supports a role for Cx36
gap junction coupling in the disruption of insulin secretion associ-
ated with Type 2 diabetes. Interestingly, some studies have shown
a correlation between Gjd2 gene and insulin gene expression; how-
ever further studies are required to elucidate this link and to iden-
tify other molecular regulators of Cx36 gene expression [30,72].
While gap junctions have been shown to be regulated through
gene transcription, environmental factors may regulate gap junc-
tion coupling in other ways. For example, as discussed above,
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• Zaprinist[99] ↑
• Norcantharidin[99] ↑
• Glibenclamide[99] ↑
• Mefloquine[98] ↓
• α-Glycyrrhetinic acid[97] ↓
• Quinine[99] ↓
• Mebeverine[99] ↓
• Gedunin[99] ↓
• Mimetic peptides[100-102] ↓
Gap Junction
Recycling
NRSE/REST
Cx36
Connexon
Cx36 Gap
Junction
Secretory
Vesicle
Fig. 3. Potential mechanisms of regulation for Cx36 gap junctions in the islet. 1. Regulation of gene expression; 2. Regulation through Phosphorylation; 3. Regulation through
connexon trafﬁcking; 4. Environmental Factors; and 5. Pharmacological Regulators. Mechanisms of regulation which have been veriﬁed for Cx36 in the islet or in MIN6 cells
are indicated in italics. Each regulator or potential regulator of Cx36 has an arrow indicating if the mechanism of action acts to increase or decrease Cx36 function.
N.L. Farnsworth, R.K.P. Benninger / FEBS Letters 588 (2014) 1278–1287 1283EphA-ephrin-A communication between islet b-cells regulates
insulin secretion [61]. However, studies in mice have shown that
Cx36 gap junction coupling is required for EphA-ephrin-A regula-
tion of insulin secretion [61]. Similarly, EphB-ephrinB signaling is
required for gap junction coupling in mesenchymal stem cells
[91]. While this may represent another mechanism of Cx36 regula-
tion, the mechanistic link between Eph-ephrin signaling and the
regulation of Cx36 in the islet is still not clear. Environmental
regulation of Cx36 is outlined in Fig. 3.
4.5. Pharmacological modulators of connexins
Pharmacological modulators of gap junction coupling are
generally non-speciﬁc and have poorly understood mechanisms
of action. Therefore, great care is required for interpreting results
with putative gap junction blockers. For example, in neuronal cells,
18-a-glycyrrhetinic acid has been found to be a potent blocker of
Cx36 gap junction coupling [96]. This blocker is often used in islets,
however non-speciﬁc effects have been observed [97]. In neuro-
blastoma cells, Meﬂoquine, an anti-malarial drug, was found to
be a potent blocker of Cx36 and Cx50 gap junction coupling [98].
However, the effect of Meﬂoquine on Cx36 gap junctions in b-cells
has not been reported. Molecules which increase gap junction cou-
pling have also not been studied in depth.
Based on the role of Cx36 in synchronizing [Ca2+]i oscillations, a
novel screen of pharmacological regulators of synchronization re-
cently identiﬁed several Cx36 blockers and activators [99]. These
compounds were conﬁrmed to modulate Cx36 translation, the size
of gap junction plaques, and gap junction coupling through dye
transfer measurements. Among many compounds, Quinine,
Mebeverine, and Gedunin decreased gap junction coupling; and
Zaprinast, Norcantharidin, and Glibenclamide increased gap junc-
tion coupling. In contrast to the dramatic effects these drugs had
on gap junction coupling; only Norcantharidin and Zaprinast had
an effect on Cx36 levels. This suggests that Glibenclamide, Quinine,Mebeverine, and Gedunin may regulate gap junction coupling
through gating or trafﬁcking, rather than expression/translation.
Interestingly, these compounds all affected the observed size of
the gap junction plaques [99]. Further investigations into the reg-
ulation of plaque formation may reveal their speciﬁc mechanisms
of action. These compounds were screened in MIN6 cells, therefore
future studies will be required to determine the efﬁcacy of these
drugs in regulating gap junctions in the islet. However this work
has provided a useful platform for several promising candidates
for gap junction modulation.
Studies in other cell types have also investigated the use of
connexin peptide mimetics: short sections of the connexin protein
which have been chemically synthesized for the modulation of gap
junctions [100]. The advantage of using peptide mimetics is that
they provide superior speciﬁcity towards connexin channels com-
pared to chemical compounds. The exact mechanism by which
these proteins inhibit gap junction coupling is not clear; however
some have suggested that they bind to connexins and prevent
proper docking in the plasma membrane, inhibiting channel for-
mation [100]. Studies in epithelial cells have shown a reversible
inhibition of [Ca2+]i signaling using Cx43 peptide mimetics, indi-
cating a decrease in gap junction coupling [101]. Peptide mimetics
have also been used as a therapeutic treatment, where a Cx43 pep-
tide mimetic increased Cx43 gene expression in cardiomyocytes
preventing cardiac arrhythmia [102]. While this approach has not
been tested in b-cells, this technique shows promise for speciﬁc
modulation of Cx36 gap junctions in the islet. All pharmacological
regulators of Cx36 are outlined in Fig. 3.
5. Potential roles for islet connexins in diabetes
5.1. Type 1 diabetes
Type 1 diabetes is characterized by the progressive destruction
of insulin producing b-cells by inﬁltrating immune cells [103].
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inﬁltrated the pancreas produce large amounts of pro-inﬂamma-
tory cytokines, including tumor necrosis factor-a (TNF-a), interleu-
kin-1b (IL-1b), and interferon-c (IFN-c). These cytokines cause
oxidative stress in the islet and can lead to b-cell apoptosis [104].
Previous studies in isolated islets have shown that pro-inﬂamma-
tory cytokines inhibit insulin secretion and lead to cell death
[105]. Chronic exposure to high levels of these cytokines is thought
to play a role in the eventual destruction of insulin producing
b-cells, leading to loss of insulin and hyperglycemia. Currently,
insulin can be used to manage the consequences of Type 1 diabe-
tes, but therapies are not available to prevent further destruction
of b-cells in the islet, although some immunomodulatory therapies
are in trials [106].
Recent studies have suggested a role for Cx36 gap junctions in
modulating cytokine-induced apoptosis [107]. These studies have
shown that a lack of cell coupling makes b-cells more susceptible
to cell death under pro-inﬂammatory cytokines, but the overex-
pression of Cx36 gap junctions protects islets from ER and oxida-
tive stress, and apoptosis induced by pro-inﬂammatory
cytokines. Evidence suggests that this is due to Cx36 gap junctions
regulating [Ca2+]i, where overexpression of Cx36 inhibits formation
of radical oxygen species and prevents depletion of ER Ca2+ stores
[95]. However further studies are required to fully understand this
mechanism. In mouse models of Type 1 diabetes, ER stress has
been shown to precede the onset of diabetes and is associated with
reduced insulin secretion [108]. Recent studies have attributed
cytokine-induced ER stress to reduced uptake of Ca2+ into intracel-
lular stores, via the sarco-endoplasmic reticulum Ca2+ ATPase
(SERCA) pump [109]. As Cx36 gap junctions regulate [Ca2+]i and
have been shown to affect Ca2+ uptake into ER stores, this suggests
a possible role for the loss of gap junction coupling following pro-
inﬂammatory cytokine induced ER stress in islet dysfunction and
b-cell death during the progression of Type1 diabetes.
While a correlation between Cx36 gap junctions and Type 1 dia-
betes has not been implicated in humans, further study may reveal
similar decreases in cell coupling in tissue from donors with recent
onset Type1 diabetes. Therapies which increase Cx36 gap junction
coupling may be able to provide protection against ER stress and b-
cell death and potentially delay the onset of disease. Studies in hu-
man islets are required to verify the role of Cx36 in cytokine in-
duced islet dysfunction, however current evidence supports
investigating this further.
5.2. Type 2 diabetes
Central to the development of Type 2 diabetes is chronic hyper-
glycemia and hyperlipidemia [110] as well as insulin resistance.
Factors derived from lifestyle or genetics play a role in disease
development, however inﬂammation resulting from high levels
of glucose and circulating free fatty acids has been shown to be a
major factor in disease development and progression [110,111].
Linked with these overt symptoms is a progressive decline in islet
function [112], however the order of progression of islet dysfunc-
tion and insulin resistance is still under debate. The gene coding
for Cx36 is located on the 14q region of chromosome 15, a suscep-
tibility locus for Type 2 diabetes, suggesting a possible connection
between Cx36 gap junction coupling and the development of Type
2 diabetes [31,113].
Although no direct for the involvement of gap junction coupling
in Type 2 diabetes has been found in humans, several animal studies
have indicated a potential link. In mice, prolonged hyperglycemia
led to decreases in b-cell coupling, Gjd2 gene expression and Cx36
protein in isolated islets [93]. Similarly, mice fed a high fat diet,
which had high levels of free fatty acids and were characterized as
pre-diabetic with increased fasting plasma insulin and glucose,had decreased Cx36 gap junction coupling [56]. The islets in these
studies function similarly to the Cx36 deﬁcientmousemodel,where
decreased glucose tolerance was observed. Decreases in Cx36 gap
junction coupling under hyperglycemic and hyperlipidemic condi-
tions will lead to a loss of synchronization of electrical activity and
[Ca2+]i oscillations. This will in turn lead to decreased 1st phase
anddisruptedpulsatile secondphase insulin secretion and therefore
reduced insulin action. Such disruptions to insulin dynamics are in
fact observed in humans with Type 2 diabetes and prediabetes, as
discussed in section C [53–55]. Studies in vitro indicate that hyper-
glycemia may act via cAMP/PKA regulated activation of ICER-1/
ICER-1c, which has been shown to bind to the Cx36 gene repressor
and down-regulate Gjd2 expression [94]. The role of radical oxygen
species has also been implicated in mediated electrical uncoupling;
however the mechanisms behind this are unclear.
Further study is needed to determine if there are disruptions to
Cx36 gap junction function in islets of Type 2 diabetes in humans.
However, a recent study suggested that a disruption to [Ca2+]i, con-
sistent with a disruption in Cx36 gap junction coupling, occurs in
humans with higher BMI suggesting this occurs in pre-diabetes
[45]. Studies which modulate Cx36 gap junction coupling in the
presence of hyperglycemia or hyperlipidemia may also help to
identify Cx36 as a novel therapeutic target. Given the implications
of Cx36 disruption in pre-diabetes and its importance in regulating
insulin release and glucose homeostasis, therapies which increase
Cx36 gap junction coupling may even delay the onset of disease.
6. Conclusions
The role of Cx36 gap junction coupling in physiological insulin
release and islet function has become increasingly well-established
over the last decade. Recent studies indicate that electrical cou-
pling is tightly linked to insulin release dynamics and regulation,
and that disruptions to this coupling can lead to a pre-diabetes-like
state. Better understanding of the role gap junction coupling plays
in islet function will further the understanding of islet biology.
Computer modeling studies of the islet may also help to predict
how changes in gap junction coupling may impact islet function
[44,114]. Of note, relatively little is understood regarding the reg-
ulation of gap junction coupling in the islet. Therefore studies are
required to understand Cx36 regulation including the role of
Cx36 interacting proteins, such as adhesion molecules and the ac-
tin cytoskeleton, as well as Cx36 gating and trafﬁcking by factors
such as cAMP, PKA, glucose among many others. Given that gap
junction regulation, including Cx36 gap junctions, is better deﬁned
in other tissue systems, established pathways for gap junction reg-
ulation exist, whose potential role in the islet can be tested. Under-
standing the regulation of Cx36 gap junction coupling in the islet is
of particular importance given the more recent evidence linking
changes in Cx36 with islet dysfunction and cell death in type1 dia-
betes, type2 diabetes, and islet function in neonatal diabetes. This
includes a novel role for Cx36 gap junction in the cytokine-medi-
ated islet dysfunction linked to the progression of Type 1 diabetes,
and down-regulation of Cx36 under conditions similar to pre-Type
2 and Type 2 diabetes. Further studies for the role of Cx36 in islet
dysfunction during the progression of diabetes are needed. How-
ever, these ﬁndings suggest that Cx36 gap junction coupling may
be a viable target for future diabetes therapies. The poor gap junc-
tion inhibitors available do present some barriers towards this,
however understanding Cx36 gap junction regulation should yield
alternative signaling pathways that can be exploited to develop
Cx36 as a therapeutic target. Finally, limited studies of gap junction
coupling have been made in human islets; therefore studies which
validate these results in human islets are also vitally needed to
determine the possibilities of Cx36 gap junction coupling as a ther-
apeutic target for human diabetes.
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